TRANSLATE

Saturday, 18 January 2014

SYMPTOMS OF PROSTATE CANCER


Not everyone experiences symptoms of prostate cancer. In many cases, signs of prostate cancer are first detected by a doctor during a routine check-up. Some men, however, will experience changes in urinary or sexual function that might indicate the presence of prostate cancer. These symptoms include: 
A need to urinate frequently, especially at night 
Difficulty starting urination or holding back urine 
Weak or interrupted flow of urine 
Painful or burning urination 
Difficulty in having an erection 
Painful ejaculation 
Blood in urine or semen 
Frequent pain or stiffness in the lower back, hips, or upper thighs 
Please note that these symptoms can also indicate the presence of other diseases or disorders of the prostate, such as benign prostate hypertrophy (BPH) (enlargement of the prostate) or prostatitis (inflammation of the prostate). More information about prostate cancer my book “Manual of prostate cancer” 


This manual is not intended as a substitute for professional healthcare. It is a preliminary guide to educate patients about treatment options and about the disease itself, so they will be better prepared to discuss it with their health care practitioners”

RADIOTERAPIA DEL CANCER DE PROSTATA


Durante las últimas décadas, la radiación externa ha evolucionado hasta ciertos niveles que actualmente permiten administrar una mayor dosis de radiación de forma segura. Por ejemplo, las técnicas de bidimensionales, que se usaban para planificación de la radioterapia  utilizados hasta principios de 1990, permitían una limitación de la dosis de irradiación hasta los 60 - 70 Gy (gray, unidad de radiación) debido a las toxicidades agudas y crónicas. Actualmente los médicos utilizan una terapia tridimensional (3D), que es una técnica mediante la cual se dirige las radiaciones hacia el tumor desde varios ángulos logrando que los órganos alrededor de la próstata reciban menos irradiación. La terapia de radiación 3D utiliza un programa informático para integrar imágenes obtenidas de un scanner de tomografía computarizada  (el cual enseña la anatomía interna del paciente) al sistema de planificación e irradiación del paciente. Las nuevas técnicas permiten a los médicos dar dosis más altas de radiación a la próstata y reducir la exposición a la radiación a los tejidos sanos cercanos. Esta nueva técnica de irradiación provoca pocos efectos secundarios. Más información del cáncer de próstata en mi libro “Cáncer de Próstata” (disponible como e-book en español)


 “Este manual no pretende ser un sustituto de la atención médica profesional. Es una fuente de información con datos actualizados y científicamente confirmados para educar a los pacientes sobre las opciones de tratamiento y de la enfermedad en sí. Este manual esta también dirigido a ayudar a los pacientes y sus familiares a estar mejor preparados para discutir dichos temas con sus médicos.”

Tuesday, 14 January 2014

INCIDENCE OF PROSTATE CANCER


Prostate cancer is the most frequent and second most lethal malignancy (cancerous growth) in men. Survival after prostate cancer diagnosis can often exceed a decade and fewer than 5% of men without metastatic disease (cancerous cell growth from an original site to one or more sites elsewhere in the body) at diagnosis will die from prostate cancer within the first 5 to 10 years after diagnosis. Prostate cancer is extremely common, affecting 15% of white men and 18% of African American men throughout their lifetime, and it will result in death in 3% of men in North America. The disease is comparable to breast cancer, which will affect 12% of women throughout their lifetime and cause death in 3%. More information about prostate cancer in my book “Manual of prostate cancer” 


 This manual is not intended as a substitute for professional healthcare. It is a preliminary guide to educate patients about treatment options and about the disease itself, so they will be better prepared to discuss it with their health care practitioners” 

INCIDENCIA DEL CANCER DE PROSTATA


El cáncer de próstata es el tumor maligno más frecuente y el segundo más letal (después del cáncer de pulmón) en los hombres. La supervivencia tras el diagnóstico de cáncer de próstata a menudo puede exceder una década. Menos del 5% de los hombres que al momento de su diagnóstico no presentan metástasis (expansión y crecimiento de células cancerosas de un sitio original para uno o más sitios en otros lugares en el cuerpo)  morirán de  esta enfermedad  entre  5 a 10 años después del diagnóstico. El cáncer de próstata es muy común y afecta a un 15% de los blancos y el 18% de los hombres afro-americanos. La enfermedad es comparable al cáncer de mama, que afecta al 12% de las mujeres y causa la muerte en el 3% de hombres en USA. Más información del cáncer de próstata en mi libro “Cáncer de Próstata” (disponible como e-book en español) 

Este manual no pretende ser un sustituto de la atención médica profesional. Es una fuente de información con datos actualizados y científicamente confirmados para educar a los pacientes sobre las opciones de tratamiento y de la enfermedad en sí. Este manual esta también dirigido a ayudar a los pacientes y sus familiares a estar mejor preparados para discutir dichos temas con sus médicos.”

Sunday, 12 January 2014

THE LANDSCAPE OF MEDICAL ONCOLOGY IN EUROPE THREATENED


Many large European countries may be facing a future shortage of medical oncologists without realizing it -- a situation that could have dire consequences for cancer patients, the European Society for Medical Oncology (ESMO) has warned.
At the European Cancer Congress today, researchers reported new data that looks at the projected number of medical oncologists in Europe and tries to predict if European countries will face a shortage of medical oncologists by 2020.
Medical oncologists are cancer specialists who focus on treating cancer using chemotherapy, targeted drugs and other medical therapies. They work together with surgeons, radiation oncologists and other specialists to deliver multi-disciplinary care to cancer patients.
The number of people who develop cancers in greater Europe is expected to grow to 3.4 million each year by 2020, a 20% increase from 2002. It is vital that countries increase their numbers of cancer specialists to match that growth, ESMO warns.
"There is increasing evidence demonstrating that limited access to a medical oncologist can lead to less timely access to anticancer treatments and therefore have a negative effect on outcomes," says Raffaele Califano, Chair of the ESMO Young Oncologists Committee and consultant medical oncologist at the Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester.
The new data reported at the conference show that adequate data on the projected numbers of medical oncologists was only available for 12 of 27 European Union nations.
"Looking at the available data, it seems that there will not be any shortage of medical oncologists in Central European and Western European countries by 2020, but the data was not available for several countries with large populations such as the Russian Federation, Turkey, Spain, Poland and Greece," said Dr Califano.
It is also important to notice that this data is based on cancer incidence and not cancer prevalence; furthermore the current economic crisis might have an influence on the number of doctors migrating to other countries.
ESMO believes that continuous monitoring from official authorities is the only way to ensure that the ratio of new cases of cancer to medical oncologists is adequate. This data would allow specialist-training programmes to be modified and new posts for medical oncologists created to maintain adequate numbers.
"This is the only way to make sure that excellent and safe standards of care for cancer patients can be maintained," Califano said.
"We believe the next step is to endeavor to collect data from the non-surveyed countries in order to have definitive information about the expected change in number of medical oncologists across all EU countries. This will help to understand fully if Europe is ready to face the new cancer cases predicted by 2020 and appropriate resources are in place," Califano said.



Source: Science Daily 

Tuesday, 24 December 2013

Sunday, 8 December 2013

ALERT! BREAST CANCER 'RISING IN UNDER-40S' ACROSS EUROPE


A latest information A study in Cancer Epidemilogy found cases rose by about 1% a year between 1990 and 2008 in seven EU countries. Rises in breast cancer rates could be caused by a range of things that can increase the risk of breast cancer, such as women having fewer children and having them later in life, or greater awareness and diagnosis in this group.
My strong recommendation to women after 40 years old is to reduce the risk of breast cancer by keeping active and cutting down on alcohol. Also get to know your breasts and, if you notice any change, tell your doctor without delay.

More info HERE  http://www.bbc.co.uk/news/health-24746437

Friday, 15 November 2013

ASPIRIN MAY ACT ON BLOOD PLATELETS TO IMPROVE SURVIVAL IN COLON CANCER PATIENTS

Dr Marlies Reimers talks with ecancer at the 2013 European Cancer Confernece in Amsterdam about how aspirin improves survival in patients diagnosed with colon cancer.
Although previous research has shown that taking low dose aspirin after being diagnosed with colon cancer improves patient outcome, the reasons why this happens remain unknown.
The new research has shown that aspirin improves outcome in patients whose tumour cells express a specific protein on their surface; the protein is known as Human Leukocyte Antigen class I (HLA class I), a cell-surface protein produced by a collection of genes involved in the functioning of the immune system.
The results mean that HLA class I could be used in the future to predict whether or not a patient would benefit from aspirin.


Source: e-cancer 
http://ecancer.org/video/2297/aspirin-may-act-on-blood-platelets-to-improve-survival-in-colon-cancer-patients.php

Monday, 4 November 2013

QUICK FACTS ABOUT OVARIAN CANCER

Most cases of ovarian cancer (cancer of the ovary) develop in women over the age of 50. The cause is not clear. Some ovarian cancers can be cured. In general, the more advanced the cancer (the more it has grown and spread), the less chance that treatment will be curative. However, treatment can often slow the progress of the cancer. Some women with a strong family history of ovarian cancer may benefit from regular screening.
Luis Mendoza, MD, PhD


Wednesday, 30 October 2013

DIET QUALITY LINKED TO PANCREATIC CANCER RISK

In a large new study of older Americans, researchers find that people with the healthiest eating habits are about 15 percent less likely to develop pancreatic cancer than those with the poorest diets.
In the analysis of data on more than 500,000 Americans over age 50, men in particular, especially those who were overweight or obese, appeared to benefit most from a high quality diet.
"It is important to note that our findings are based on overall diet and not individual foods. A combination of many foods contributed to the observed association between greater compliance with the Dietary Guidelines and lower risk of pancreatic cancer," lead author Hannah Arem of the National Cancer Institute in Bethesda, Maryland, told Reuters Health in an email.
Though pancreatic cancer is rare - about 1.5 percent of Americans will develop the disease during their lifetimes - it is one of the most aggressive and lethal cancers. Only about six percent of people with pancreatic cancer are still alive five years after diagnosis, according to Arem.
Past studies looking at the relationship between diet and risk for pancreatic cancer have tended to focus on individual foods and found few connections, according to her team's report, published in the Journal of the National Cancer Institute.
To examine links between overall diet and cancer risk, Arem and her colleagues used the government-designed Healthy Eating Index published in 2005 (HEI-2005) as a basis for rating the overall quality of people's diets.
They applied those criteria to responses from 537,218 men and women who were part of the American Association for Retired Persons Diet and Health Study. Between 1995 and 1996, participants filled out diet questionnaires about how often they ate items on a list of 124 foods.
Arem's team then divided participants into five groups based on how closely their diets met HEI-2005 recommendations for consuming healthy foods such as fruits, vegetables and whole grains and limiting unhealthy ones, like red meat and junk foods.
Scores on the index range from 0 (no guidelines met) to 100 (all guidelines met), with high scores indicating the healthiest eating patterns.
Using state cancer registries and Social Security Administration data, the researchers followed participants for about 10 years and found that 2,383 people developed pancreatic cancer.
About 22 percent of the pancreatic cancer cases were among people with the lowest HEI-2005 scores, while 19 percent were in people with the highest scores. Overall, that translates to a 15 percent lower risk among those with the healthiest diets.
Among men who were overweight or obese, however, those with healthy eating scores in the top-fifth group were 28 percent less likely than their counterparts in the bottom-fifth to develop pancreatic cancer. The same effect was not seen among overweight women.
When the researchers adjusted for other factors linked to pancreatic cancer risk, including smoking, alcohol consumption and diabetes, the effects of diet quality remained the same.
Arem's team also looked at specific subgroups of foods and found that people who ate the greatest amounts of certain healthy foods, such as dark-green and orange vegetables, legumes, whole grains and low-fat milk had lowered risk for pancreatic cancer.
The researchers point out in their report, though, that other recent reviews of the literature have not found similar results for people who ate lots of fruits and vegetables, for example.
"Our study showed an association between diet and pancreatic cancer risk, rather than cause and effect. In general, maintaining a healthy diet has many health benefits," Arem said.
Dr. Rachel Ballard-Barbash, also of the National Cancer Institute, and her colleagues also note in an editorial accompanying the new study that attempts to link individual foods or nutrients to cancer risk have yielded conflicting results.
While some understanding about the relationship between diet and certain cancers has been gained, that "knowledge has not yet translated into noticeable reductions in the incidence of the major cancers with diet-related etiology," they write.
Dr. Alfred Neugut, who studies digestive cancers and epidemiology but was not involved in the current research, agreed there are still a lot of unknowns about the links between diet and cancer.
"If you go out of your way to have a healthy diet, then you're probably going out of your way to be healthy in other ways," Neugut, a professor of medicine at Columbia Presbyterian Medical Center in New York, told Reuters Health. So it's difficult to tease out whether it's really the diet alone that explains the decreased risk seen in the new study.
"It's always safe to say that it's prudent to eat a healthy diet," he said. But, he added, "I would say that diet and cancer is a topic that, despite huge numbers of studies and huge amounts of money invested, has eluded any dramatic findings."

Source: Reuters